Compare IMCR & DAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | DAC |
|---|---|---|
| Founded | 2008 | 1972 |
| Country | United Kingdom | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2021 | 2006 |
| Metric | IMCR | DAC |
|---|---|---|
| Price | $34.82 | $94.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $67.00 | ★ $105.00 |
| AVG Volume (30 Days) | ★ 269.1K | 68.7K |
| Earning Date | 11-06-2025 | 02-09-2026 |
| Dividend Yield | N/A | ★ 3.79% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 25.05 |
| Revenue | $379,590,000.00 | ★ $1,034,370,000.00 |
| Revenue This Year | $32.28 | N/A |
| Revenue Next Year | $10.66 | $1.29 |
| P/E Ratio | ★ N/A | $3.79 |
| Revenue Growth | ★ 28.11 | 2.90 |
| 52 Week Low | $23.15 | $65.40 |
| 52 Week High | $40.72 | $100.00 |
| Indicator | IMCR | DAC |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 48.48 |
| Support Level | $35.41 | $93.65 |
| Resistance Level | $36.64 | $95.47 |
| Average True Range (ATR) | 1.51 | 1.66 |
| MACD | -0.25 | -0.16 |
| Stochastic Oscillator | 3.99 | 52.45 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.